TG Therapeutics Inc（TGTX）の株式分析TGTXTG Therapeutics Inc

TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

TG Therapeutics Inc (TGTX) is currently a hold. The stock is priced at $53.97, which is significantly below the analyst price target of $78, indicating potential upside. However, the RSI is at 43.87, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the stock has seen a recent 5-day change of -2.53% and a year-to-date increase of 84.32%, reflecting volatility in the short term. The main risk is the recent earnings report where EPS came in at $0.05, significantly below estimates of $0.41, which may affect investor sentiment in the near term.

5 analysts cover TGTX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 43.50.